RXi Pharma Licenses Thermo Fisher's RNAi Sequences for Drug Programs

Dec 14, 2007

NEW YORK (GenomeWeb News) – CytRx subsidiary RXi Pharmaceuticals has licensed RNAi sequences from Thermo Fisher Scientific to a number of target genes for use in the development of therapeutic compounds for several common diseases, RXi said today.

Under the agreement, RXi will use RNAi sequences generated by Thermo Fisher Dharmacon’s sequence selection algorithm for its rxRNA compound program, which focuses on developing therapeutics for type 2 diabetes, obesity, neurology, and oncology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Warren Releases Genetic Ancestry Results

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Thirty-One Recommended for Removal

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz Dies

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

This Week in PLOS

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.

Main menu